glp 1 for ckd Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection Real-World Evidence for GLP-1 Receptor

If a product has not been FDA-approved for a specific condition, it cannot be promoted as safe or effective for that condition

The onus of lawful, safe, and appropriate use rests entirely with the purchaser

Greger cuts through the promotional puffery and presents the pros and cons of these weight-loss drugs so individuals can make up their own mind in the face of the very real and devastating consequences of obesity

Rybelsus and Farxiga treat Type 2 diabetes, but one has more approved uses, among other differences, such as cost and side effects.

What are they

Surgery timing with GLP-1 therapy requires careful planning